Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention?

J Support Oncol. 2010 Jul-Aug;8(4):162-3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • ErbB Receptors / antagonists & inhibitors
  • Exanthema / chemically induced*
  • Exanthema / prevention & control
  • Humans
  • Palliative Care*

Substances

  • Antineoplastic Agents
  • ErbB Receptors